

## Original Research Article

Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* isolates in a Senegalese university teaching hospital

**Comment [M1]:** Capitalised each word with exception of baumannii

### Abstract

**Background:** The emergence and spread of carbapenem-resistant *Acinetobacter baumannii* are critical in hospitals, particularly in intensive care units (ICUs), which represents a public health concern worldwide. In this study, we investigated the molecular epidemiology of multi-drug resistant *A. baumannii* (MDR-AB) in Dakar, Senegal.

**Methods:** A total of 29 strains of MDR-AB were isolated from patients hospitalized at Aristide Le Dantec University teaching hospital in Dakar, Senegal. The isolates were identified by API 20NE strip test and MALDI-TOF. The antimicrobial susceptibility testing was performed using the disk diffusion method. Simplex- and multiplex-polymerase chain reactions with appropriate primers were used to detect and sequence the following  $\beta$ -lactamase genes: two class D carbapenem hydrolyzing oxacillinases (*bla*<sub>OXA-51</sub> and *bla*<sub>OXA-23</sub>), three class B metallo- $\beta$ -lactamase genes (*bla*<sub>IMP</sub>, *bla*<sub>VIM</sub> and *bla*<sub>NDM</sub>), and five class A  $\beta$ -lactamase genes (*bla*<sub>PER</sub>, *bla*<sub>SHV</sub>, *bla*<sub>VEB</sub>, *bla*<sub>TEM</sub>, and *bla*<sub>GES</sub>).

**Results:** Among the 29 MDR-AB strains, 11 (37.9%) were isolated from ICUs, 5 (17.2%) from pediatric surgery, and 13 (44.8%) from other departments. These MDR strains were mainly isolated from urine and pus samples (41.4% and 31.0%, respectively). All isolates were positive for the *A. baumannii* specific gene *bla*<sub>OXA-51</sub>. The *bla*<sub>OXA-51</sub> and *bla*<sub>OXA-23</sub> genes coexisted in 26 (89.65%) of the strains. The *bla*<sub>IMP</sub> and *bla*<sub>VIM</sub> genes were not detected among the selected strains. Interestingly, 1 strain elicited the gene coding for metallo- $\beta$ -lactamase NDM-1. Three isolates turned out to produce the penicillinase TEM-2.

**Conclusions:** Carbapenem resistance in Senegalese strains of *A. baumannii* is predominantly due to the worldwide disseminated gene *bla*<sub>OXA-23</sub>, with a subset of strains due to NDM-1. Systemic molecular surveillance network should be established for further efficient monitoring of MDR strains in Senegal.

**Keywords:** *Acinetobacter baumannii*; Carbapenemase; Molecular epidemiology.

**Word count:** 265

**Comment [M2]:** Move to the results section of the abstract

**Comment [M3]:** The *A. baumannii* was

**Comment [M4]:** using

**Comment [M5]:** state the type of sample used for the isolation of *A. baumannii*

**Comment [M6]:** Delete

**Comment [M7]:** *bla*<sub>TEM</sub>, and

**Comment [M8]:** strains isolated,

**Comment [M9]:** The

**Comment [M10]:** delete

**Comment [M11]:** samples with no.(41.4%) and no.(31.0%) respectively.

**Comment [M12]:** Moreover,

**Comment [M13]:** 1(...%)

**Comment [M14]:** Used numeric character and also include its percentage in bracket

**Comment [M15]:** and TEM-2

**Comment [M16]:** also include simple and multiplex PCR, NDM-1, TEM-2

**Comment [M17]:** delete

## Introduction

*Acinetobacter* is a gram-negative aerobic bacilli or coccobacilli that belong to the *Moraxellaceae* family [1]. They are ubiquitous and can survive on dry surfaces for up to a month, are frequently carried on the skin of healthcare workers, and increase the likelihood of both colonizing patients and contaminating medical equipment. There are several species of *Acinetobacter* which can cause disease in humans, and *A. baumannii* accounts for almost 80% of infections [2]. *A. baumannii* infections usually occur in patients hospitalized in intensive care units (ICU) [3] and may cause important nosocomial infections [4]. City-acquired infections, especially pneumonia, are more common in tropical climates settings [5]. *A. baumannii* infection is associated with 19 to 54% mortality [6].

Nosocomial *Acinetobacter* pneumonia is frequently multi-lobar and complicated. *A. baumannii* can also cause wound and suppurative infections (e.g. abscesses) in any organ, including the lungs, urinary tract, skin, and soft tissue. Bacteremia and septic shock can occur from *A. baumannii* infection, and both are associated with a poor prognosis. *Acinetobacter* organisms can cause meningitis (mainly after a neurosurgical procedure), cellulitis, or phlebitis on indwelling venous catheter, eye infections, endocarditis on native valve or prosthesis, osteomyelitis, septic arthritis, or abscesses of the pancreas and liver. The significance of the isolation of *Acinetobacter* in clinical specimens, such as respiratory secretions in case of intubation or in specimens from open wounds, is difficult to interpret as it is often only responsible for colonization [2; 7].

*A. baumannii* has long exhibited inherent resistance to many antimicrobials. Multidrug resistant (MDR) *A. baumannii* strains are defined as strains active in at least 3 classes of antimicrobials; some MDR isolates are resistant to all antimicrobials. Severe infections with *A. baumannii* are often treated by combining antibiotics: carbapenems (imipenem or meropenem) or ampicillin/sulbactam plus an aminoglycoside; the colistin-minocycline combination is the last treatment choice used in cases of extreme resistance [8]. For over 20 years, cases of acquired resistance of *A. baumannii* to carbapenems have been increasingly reported in all continents [9]. Until the discovery in 2011 of the genes encoding resistance to beta-lactams, tetracyclines, and glycopeptides, the excessive consumption of antibiotics were suspected as the main cause of the emergence of resistance genes [10]. With the increase in MDR bacteria, imipenem has become the drug of last choice for the treatment of nosocomial infections caused by *A. baumannii*. However, their efficacy is being increasingly compromised by the emergence of carbapenem-hydrolyzing beta-lactamases of molecular Ambler class B (VIM, IMP) and class D (OXA-23, OXA-58) [11].

**Comment [M18]:** please rewrite your introduction. It should not be more than 1 page.

In Africa, high rates of MDR *A. baumannii* infection have been demonstrated in several countries. Ugochukwu et al., in 2014, Lowe et al., in 2018, and Ben Cheikh et al., in 2018 evaluated the epidemiology of MDR of *A. baumannii* in Nigeria, South Africa, and Tunisia, respectively, which showed that the rate of MDR of *A. baumannii* ranged from 13 to 89% [12-14]. The main mechanism of resistance to carbapenems in Africa is represented by the production of OXA<sub>23</sub> [15].

The recognition of MDR isolates is a major laboratory challenge, and their inappropriate or delayed detection may have negative impacts on patient management and on the implementation of infection control measures [9]. To the best of our knowledge, very few studies were carried out on molecular characterization of carbapenem-resistant *A. baumannii* clinical isolates in Senegal. The aim of this study was to evaluate molecular epidemiology of MDR *A. baumannii* (MDR-AB) isolated in Aristide Le Dantec hospital, the major University Teaching Hospital in Dakar, Senegal.

## Materials and Methods

### Bacterial isolates

A total of 33 non-duplicate suspected MDR-AB strains were isolated from patients hospitalized in intensive care units (ICUs), pediatric surgery, and other departments of Aristide Le Dantec University hospital in Dakar, Senegal.

Clinical specimens were cultured on Eosin Methylene Blue (EMB) agar (Merck, Germany), and incubated at 37°C for 24 h. Clinical isolates were identified using an API 20NE strip test (bioMérieux, Durham, USA). Species confirmation was performed using Matrix-Assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF) system (Bruker Daltonik, GmbH, Bremen, Germany).

### Antibiotic susceptibility testing

Antimicrobial susceptibility testing was performed using the disk diffusion method (Bio-Rad, France), as recommended by the Antibigram Committee of the French Society for Microbiology (CA-SFM, 2015) [16]. Briefly, bacterial suspensions at 10<sup>7</sup> CFU/ml, adjusted with a McFarland densitometer, were inoculated on Mueller-Hinton agar and incubated for 16 to 24 hours at 37 °C. The following antibiotics were tested: ticarcillin, (TIC, 75 µg), clavulanic acid/ticarcillin (TCC, 10/75 µg), clavulanic acid/amoxicillin (AMC, 10/20 µg), piperacillin (PIP, 100 µg), tazobactam/piperacillin (TZP, 10/100 µg), ceftazidime (CTZ, 30 µg),

**Comment [M19]:** Isolation of *A. baumannii*

**Comment [M20]:** Shift the sentence back to form one paragraph

**Comment [M21]:** Be specific "24hours"

ceftazidime (CAZ, 30 µg), cefepime (30 µg), aztreonam (ATM, 30 µg), imipenem (IMP, 10 µg), meropenem (MEM, 10 µg), gentamicin (GM, 10 µg), and tobramycin (TB, 30 µg), amikacin (AN, 30 µg), ciprofloxacin (CIP, 5 µg), and colistin (CST, 30 µg) *Pseudomonas aeruginosa* ATCC 278539 were used for quality control.

**Comment [M22]:** (CST, 30 µg).

### PCR and sequencing of $\beta$ -lactamase genes

Total DNA was extracted from the bacterial isolates using the MagAttract HMW DNA Kit (Qiagen, Hilden, Germany), according to the manufacturer's instruction. Genes coding for OXA carbapenemase genes grouped into two class D carbapenem hydrolyzing oxacillinases (*bla*<sub>OXA-51</sub>, and *bla*<sub>OXA-23</sub>), three class B metallo- $\beta$ -lactamase genes (*bla*<sub>IMP</sub>, *bla*<sub>VTM</sub> and *bla*<sub>NDM</sub>), and five class A  $\beta$ -lactamase genes (*bla*<sub>PER</sub>, *bla*<sub>SHV</sub>, *bla*<sub>VEB</sub>, *bla*<sub>TEM</sub>, and *bla*<sub>GES</sub>) were sought by Simplex- and multiplex-polymerase chain reaction. The total information of the PCR primers utilized in our study is shown in table 1. Each PCR reaction mix comprised 100 ng genomic DNA, 50 µL Nuclease-free water, 0.5 U Taq DNA Polymerase (5U/µL), 10 µL 5x MyTaq<sup>TM</sup> Red Reaction Buffer, and 1 µL of each primer, in a total volume of 50 µL. The PCR reactions were initially denatured at 95°C for 1 minute, followed by 30 cycles of denaturation at 95°C for 15 seconds, and annealing at 60°C for 15 seconds, with a final extension at 72°C for 15 seconds. The PCR products were separated by 1.5% agarose gel electrophoresis and visualized using ethidium bromide staining and UV light.

**Comment [M23]:** Add citation to the methodology

**Comment [M24]:** Include the picture of your gel showing the different bands

**Table 1.** Oligonucleotide primers sequence used for PCR and sequencing of *Acinetobacter baumannii*.

| Targets                           | Primer names  | Primer sequences                   | Position from ATG |
|-----------------------------------|---------------|------------------------------------|-------------------|
| <i>bla</i> <sub>OXA-23</sub>      | MOXA-23-F1    | GAT-CGG-ATT-GGA-GAA-CCA-GA         | 261-280           |
|                                   | MOXA-23-R1    | ATT-TCT-GAC-CGC-ATT-TCC-AT         | 742-761           |
| <i>bla</i> <sub>OXA-51</sub>      | MOXA-51-F1    | TAA-TGC-TTT-GAT-CGG-CCT-TG         | 252-273           |
|                                   | MOXA-51-R1    | TGG-ATT-GCA-CTT-CAT-CTT-GG         | 588-607           |
| <i>bla</i> <sub>VIM</sub> group 1 | MuVIM-gr1-F1  | GCW*-AGT-CCG-TTA-GCC-CAT-T         | 58-77             |
|                                   | MuVIM1-gr1-R1 | R*R*C-GAC-TGA-GCG-ATT-TK*T-GT      | 776-796           |
| <i>bla</i> <sub>VIM</sub> group 2 | SeqVIM2-Fw1   | TGT-TCA-AAC-TTT-TGA-GTA-AGT-TAT-TG | 2-28              |
|                                   | SeqVIM2-Rv2   | ACT-GAG-CGA-TTT-GTG-TGC            | 774-792           |
| <i>bla</i> <sub>NDM</sub>         | MuNDM-F1      | GGG-ATT-GCG-ACT-TAT-GCC-AA         | 406-426           |
|                                   | MuNDM-R1      | TGG-CTC-ATC-ACG-ATC-ATG-CT         | 730-750           |
| <i>bla</i> <sub>IMP</sub>         | IMP1-2-F      | GTT-TAT-GTT-CAT-ACW*-TCG-TT        | 99-119            |
| <i>bla</i> <sub>PER</sub>         | MuPER-F2      | TGC-ATC-AGG-TB*G-ATC-AGG-G         | 245-26            |
|                                   | MuPER-R2      | GY*G-CTT-CAT-TTG-CK*A-CCA-C        | 499-518           |
| <i>bla</i> <sub>SHV</sub>         | MuSHV-F1      | CGC-CAT-TAC-CAT-GAG-CGA-TAA        | 363-38            |
|                                   | MuSHV-R1      | CCC-GCA-GAT-AAA-TCA-CCA-CAA        | 761-782           |
| <i>bla</i> <sub>VEB</sub>         | MuVEB-F1      | CCC-GAT-GCA-AAG-CGT-TAT-GA         | 192-21            |
|                                   | MuVEB-R1      | CCG-GAA-GTC-CCT-GTT-TTA-TGA-G      | 704-726           |
| <i>bla</i> <sub>TEM</sub>         | MuTEM-F1      | TCT-CAA-CAG-CGG-TAA-GAT-CCT        | 144-165           |
|                                   | MuTEM-R1      | TCA-GTG-AGG-CAC-CTA-TCT-CAG        | 827-848           |
| <i>bla</i> <sub>GES</sub>         | GES-1A        | ATG-CGC-TTC-ATT-CAC-GCA-C          | 1-19              |
|                                   | GES-1B        | CTA-TTT-GTC-CGT-GCT-CAG-G          | 844-863           |

## Statistical analysis

Differences in categorical variables between groups were analyzed using Fisher's exact tests. The level of significance for all statistical tests was set at  $p < 0.05$ . Statistical analyses were performed with Epi Info (version 7, CDC, USA) software.

## Results and Discussion

### Epidemiology data

Of the 33 isolates initially collected and identified with API NE, 29 isolates were confirmed as *A. baumannii* by MALDI-TOF, and the presence of *bla*<sub>OXA-51</sub>-like gene. All 29 confirmed *A. baumannii* species were MDR pattern. Of these, 37.9% (n = 11; 95% CI 20.7-57.7), 31.0% (n = 9; 95% CI 15.3-50.8) and 17.2% (n = 5; 95% CI 5.8-35.8) were collected from patients hospitalized in intensive care units (ICUs), general surgery and pediatric surgery, respectively (table 2). Most of the MDR-AB strains (41.4%; n = 12, 95% CI 21.5-63.1) were found in urine samples. Only 2 (6.9%, 95% CI 0.8-22.8) were isolated from bronchial secretions.

**Table 2:** Distribution of carbapenem-resistant *Acinetobacter baumannii* according to services and pathological products.

| Parameters           |           |             |
|----------------------|-----------|-------------|
|                      | n, (%)    | 95% CI      |
| <b>Hospital unit</b> |           |             |
| ICUs                 | 11 (37.9) | 20.7 - 57.7 |
| Pediatric surgery    | 5 (17.2)  | 5.8 - 35.8  |
| general surgery      | 9 (31.0)  | 15.3 - 50.8 |
| Other                | 4 (13.8)  | 3.9 - 31.7  |
| <b>Specimen type</b> |           |             |
| Blood                | 5 (17.2)  | 5.8 - 35.5  |
| Puncture liquid      | 1 (3.4)   | 0.1 - 17.8  |
| Pus                  | 9 (31.0)  | 15.3 - 50.8 |
| bronchial secretions | 2 (6.9)   | 0.8 - 22.8  |
| Urines               | 12 (41.4) | 23.5 - 61.1 |

**Comment [M25]:** Distribution of carbapenem-resistant *A. baumannii*

**Comment [M26]:** Replace with "isolated"

**Comment [M27]:** Please explain how they are MDR pattern ?

**Comment [M28]:** 11(37.9%), 9(31.0%), and 5(17.2%)

**Comment [M29]:** 12(41.4%)

**Comment [M30]:** 2(6.9%)

**Comment [M31]:** secretions as described in Table 2.

**Comment [M32]:** What is the statistical inference to this table, add p value at the end of the table

**Comment [M33]:** Departments/Types of samples

### Susceptibility profiles of *Acinetobacter baumannii* isolates to antimicrobial agents

The results of *A. baumannii* susceptibility profile was depicted in table 3. All isolates were resistant to clavulanic acid/amoxicillin and clavulanic acid/ticarcillin combinations, aztreonam, cefoxitin, ciprofloxacin, pefloxacin, piperacillin, and ticarcillin. There was no statistically significant difference between the ICU and paediatric department. Among the aminoglycosides tested, gentamicin, tobramycin, and amikacin remained active in 13.8% (n = 4, 95% CI 3.9- 31.7), 31.0% (n = 9, 95% CI 15.3- 50.8), and 75.9% (n = 22, 95% CI 56.5 - 89.7) of cases, respectively. Interestingly, all these MDR isolates were susceptible to colistin.

**Table 3:** Antimicrobial Susceptibility for *Acinetobacter baumannii*.

| Antibiotics                 | Resistant |             | Susceptible |             |
|-----------------------------|-----------|-------------|-------------|-------------|
|                             | n (%)     | 95% CI      | n (%)       | 95% CI      |
| Amoxicillin/Clavulanic acid | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Ticarcillin/Clavulanic acid | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Amikacin                    | 7 (24.1)  | 10.3 - 43.5 | 22 (75.9)   | 56.5 - 49.7 |
| Aztreonam                   | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Cefepime                    | 26 (89.7) | 72.6 - 97.8 | 3 (10.3)    | 2.2 - 7.4   |
| Cefoxitin                   | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Ceftazidime                 | 24 (82.8) | 64.2 - 94.2 | 5 (17.2)    | 5.8 - 35.8  |
| Ciprofloxacin               | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Colistin                    | 0 (0)     | 0 - 0       | 29 (100)    | 100 - 100   |
| Gentamicin                  | 25 (86.2) | 68.3 - 96.1 | 4 (13.8)    | 3.9 - 31.7  |
| Piperacillin                | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Imipenem                    | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Meropenem                   | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Piperacillin/Tazobactam     | 28 (96.6) | 82.2 - 99.9 | 1 (3.4)     | 0.1 - 17.8  |
| Ticarcillin                 | 29 (100)  | 100 - 100   | 0 (0)       | 0 - 0       |
| Tobramycin                  | 20 (69)   | 49.2 - 84.7 | 9 (31)      | 15.3 - 50.8 |

**Comment [M34]:** *A. baumannii*

**Comment [M35]:** How significant ? state the p value to support the explanation.

**Comment [M36]:** Remove all the CI from the results explanation. Only report the no.(%).

**Comment [M37]:** Delete

**Comment [M38]:** Antimicrobial susceptibility profile of *A. baumannii*

**Comment [M39]:** What happen here ?

### Carbapenemase genes

Table 4 shows the distribution of carbapenem resistance genotypes. The genes encoding *bla<sub>VIM</sub>*, *bla<sub>IMP</sub>*, *bla<sub>VIM</sub>*, *bla<sub>PER</sub>*, *bla<sub>SHV</sub>*, *bla<sub>VEB</sub>*, and *bla<sub>GES</sub>* were not detected in our study. All 29 isolates (87.9%; 95% CI 78.8 - 96.6) were positive for the *A. baumannii* specific gene *bla<sub>OXA-51</sub>*. The *bla<sub>OXA-51</sub>* and *bla<sub>OXA-23</sub>* genes coexisted in 25 isolates (89.7%; 95% CI 68.3 - 96.1). Among the 25 *bla<sub>OXA-23</sub>* positive strains, 3.4% (n = 1; 95% CI 0.1 - 17.8) expressed the gene

**Comment [M40]:** What is you p value ?

**Comment [M41]:** the heading should be "Distribution of carbapenemase-encoding genes"

**Comment [M42]:** Write n(%) only

coding *bla*<sub>TEM</sub>. Interestingly, among the 29 MDR-AB, 3.4% (n = 1; 95% CI 0.1 - 17.8) and 6.9% (n = 2; 95% CI 0.8 - 22.8) were positive for *bla*<sub>NDM-1</sub> and *bla*<sub>TEM-2</sub>, but not *bla*<sub>OXA-23</sub>.

**Table 4.** Distribution of carbapenemase-encoding genes in *Acinetobacter baumannii* strains.

| Carbapenemases-encoding genes                                                             | Number (%) | 95% CI      |
|-------------------------------------------------------------------------------------------|------------|-------------|
| <i>bla</i> <sub>OXA-51</sub> only                                                         | 29 (100)   | -           |
| <i>bla</i> <sub>OXA-51</sub> and <i>bla</i> <sub>OXA-23</sub>                             | 25 (86.2)  | 68.3 - 96.1 |
| <i>bla</i> <sub>OXA-51</sub> <i>bla</i> <sub>OXA-23</sub> and <i>bla</i> <sub>TEM-2</sub> | 1 (3.4)    | 0.1 - 17.8  |
| <i>bla</i> <sub>OXA-51</sub> and <i>bla</i> <sub>NDM-1</sub>                              | 1 (3.4)    | 0.1 - 17.8  |
| <i>bla</i> <sub>OXA-51</sub> and <i>bla</i> <sub>TEM-2</sub>                              | 2 (6.9)    | 0.8 - 22.8  |

**Comment [M43]:** Check and reconcile the results here and those in Table 4. Especially, the result of *bla*<sub>OXA-51</sub> gene ; and *bla*<sub>OXA-51</sub> and *bla*<sub>OXA-23</sub>

The *bla*<sub>OXA-23</sub> positive strain was more resistant to antibiotics than strains that harbor both *bla*<sub>OXA-23</sub> and *bla*<sub>TEM-2</sub> (table 5). We also found that the *bla*<sub>TEM</sub> positive strain was susceptible to tobramycin and amikacin. In contrast, the strains positive for both the *bla*<sub>NDM-1</sub>, and *bla*<sub>TEM-2</sub> genes were all resistant to gentamicin and tobramycin (table 5).

**Comment [M44]:** Add heading here " Antibiotic susceptibility profiles of carbapenemase-encoding genes of *A. baumannii*"

**Comment [M45]:** What is your p value for Table 4 ?

**Comment [M46]:** as shown in Table 5.

**Table 5.** Distribution of carbapenemase-encoding genes *Acinetobacter baumannii* and its antibiotic susceptibility profiles.

| Antibiotic                  | Resistant<br>n (%)           |                             |                             |                                                                 | Susceptible<br>n (%)         |                             |                             |                                                                 | p      |
|-----------------------------|------------------------------|-----------------------------|-----------------------------|-----------------------------------------------------------------|------------------------------|-----------------------------|-----------------------------|-----------------------------------------------------------------|--------|
|                             | <i>bla</i> <sub>OXA-23</sub> | <i>bla</i> <sub>NDM-1</sub> | <i>bla</i> <sub>TEM-2</sub> | <i>bla</i> <sub>OXA-23</sub> and<br><i>bla</i> <sub>TEM-2</sub> | <i>bla</i> <sub>OXA-23</sub> | <i>bla</i> <sub>NDM-1</sub> | <i>bla</i> <sub>TEM-2</sub> | <i>bla</i> <sub>OXA-23</sub> and<br><i>bla</i> <sub>TEM-2</sub> |        |
| Amoxicillin/Clavulanic acid | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 1 (3.4%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          |        |
| Ticarcillin/Clavulanic acid | 25 (86.2%)                   | 1 (100%)                    | 2 (100%)                    | 1 (100%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | -      |
| Amikacin                    | 7 (28%)                      | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | 18 (72%)                     | 1 (100%)                    | 2 (100%)                    | 1 (100%)                                                        | .687   |
| Aztreonam                   | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 1 (3.4%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | -      |
| Cefepime                    | 25 (100%)                    | 1 (100%)                    | 0(0%)                       | 0 (0%)                                                          | 0 (0%)                       | 0 (0%)                      | 2 (100%)                    | 1 (100%)                                                        | < .001 |
| Cefoxitin                   | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 1 (3.4%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | -      |
| Ceftazidim                  | 23 (92%)                     | 1 (100%)                    | 0 (0%)                      | 0 (0%)                                                          | 2 (8%)                       | 0 (0%)                      | 2 (100%)                    | 1 (100%)                                                        | < .001 |
| Ciprofloxacin               | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 1 (3.4%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | -      |
| Colistin                    | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 1 (3.4%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | -      |
| Gentamicin                  | 21 (84%)                     | 1 (100%)                    | 2 (100%)                    | 1 (100%)                                                        | 4 (16%)                      | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | .863   |
| Piperacillin                | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 1 (3.4%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | -      |
| Imipenem                    | 24 (96%)                     | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | 1 (4%)                       | 1 (100%)                    | 2 (100%)                    | 1 100%                                                          | <.001  |
| Meropenem                   | 24 (96%)                     | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | 1 (4%)                       | 1 (100%)                    | 2 (100%)                    | 1 100%                                                          | <.001  |
| Piperacillin/Tazobactam     | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 0 (0%)                                                          | 0(100%)                      | 0 (0%)                      | 0 (0%)                      | 1 (100%)                                                        | < .001 |
| Ticarcillin                 | 25 (100%)                    | 1 (100%)                    | 2 (100%)                    | 1 (3.4%)                                                        | 0 (0%)                       | 0 (0%)                      | 0 (0%)                      | 0 (0%)                                                          | -      |

**Comment [M47]:** *A. baumannii*

Tobramycin 19 (95%) 1 (100%) 0 (0%) 0 (0%) 6 (5%) 0 (0%) 2 (100%) 1 (100%) < .001

In this study, we evaluated the molecular epidemiology of *A. baumannii* resistance to carbapenems, particularly imipenem, in patients at Aristide Le Dantec university teaching hospital. A total of 29 strains collected from patient's specimen in different hospital departments were identified using API NE galleria, MALDI-TOF mass spectrometry, and the presence of *bla*<sub>OXA-51</sub> gene detected by PCR. Our confirmation of *A. baumannii* by *bla*<sub>OXA-51</sub> was higher than what was previously carried out in Senegal [17].

Our results showed that the majority of *A. baumannii* strains (39%) have been isolated from patients hospitalized in intensive care units (ICU), as previously reported in Africa, China, Europa, and America [17-21].

In this present study, these *A. baumannii* strains were mainly isolated from urine (41.4%), pus (31.0%), and blood (17.2%) samples. A study done by Nadia Jaidane et al., in 2016 from the University Hospital of Sahloul (Tunisia) reported 38.2% of *A. baumannii* isolates from blood [19]. Hilina Maitbonor et al., in 2018 from Ethiopia reported lower rates of 5% and 4.1% of *A. baumannii* isolates respectively from blood and urine cultures [22].

We found high resistance rates to beta-lactam and aminoglycosides antibiotic classes. Resistance to beta-lactams was associated with other antibiotics families, such as aminoglycosides including gentamicin (84.8%), tobramycin (69%) and amikacin (24,1%), and fluoroquinolones (ciprofloxacin: 100%). Recently, a study conducted by Anane et al., in South Africa showed that more than 81% of *A. baumannii* clinical isolates had shown that resistance to beta-lactams were associated with those of other families of antibiotics such as aminoglycosides and fluoroquinolones with resistance rates ranging from 50 to 87% [18].

CRAB has become a real health problem. In our studies all strains of *A. baumannii* were resistant to carbapenems. In Ethiopia, Germany Italy and China, the proportion of *A. baumannii* isolates resistant to carbapenem increased from 13,5% to 98,7% [21-24]. Carbapenems are generally considered to be the most effective antibacterial agents for treatment of multidrug-resistant bacterial infections, including Gram-negative bacilli. However, with widespread use of these antibiotics, the prevalence of bacterial resistance to carbapenems has increased rapidly. This increase in *Acinetobacter* species could be explained, in large part, to the association of resistance mechanisms: over expression of low-spectrum beta-lactamases extended with efflux pumps, impermeability, or expression of carbapenem-hydrolyzing beta-lactamases, known as carbapenemases [25]. In this study, carbapenemase-encoding genes were investigated to decipher the mechanism of carbapenem resistance. Molecular detection of carbapenemase-encoding genes has shown that the

Comment [M48]: add line spacing

Comment [M49]: do not keep repeating your results

Comment [M50]: delete

Comment [M51]: you have already discuss it above. You don't need to repeat the results, just talk about the highest and the lowest with out mention the figures, and then relate it with other studies.

Comment [M52]: Delete

Comment [M53]: Delete

Comment [M54]: Delete

Comment [M55]: Anane et al., [18]

Comment [M56]: Delete

Comment [M57]: 13.5%

Comment [M58]: 98.7%

Comment [M59]: Move to next page

production of OXA-type carbapenemase is predominant in *A. baumannii* [26]; the *bla*<sub>OXA-51-like</sub> gene was detected in all 29 strains of *A. baumannii*, *bla*<sub>OXA-23</sub> is frequently found in health facilities, and known as a worldwide disseminated gene [27]. Our results showed that *bla*<sub>OXA-23</sub> was the second predominant mechanism of resistance to carbapenems, with 89.7% of prevalence rate. This rate was higher than previously reported in Senegal, showing a prevalence of 15.38% [17]. High prevalence of MDR *A. baumannii* harboring *bla*<sub>OXA-23-like</sub> have been reported in some African countries, namely South Africa (70%), Tunisia (93.9%) and Libya (70%) [18; 19; 28]. Studies carried out in South America (Argentina, Ecuador, Chile, Bolivia, Uruguay, and Paraguay) showed that the *bla*<sub>OXA-23</sub> gene was recovered in all participating medical centers and in all isolates from seven of nine centers with an overall prevalence of 76.9% [29]. In Asia, particularly in Saudi Arabia, *bla*<sub>OXA-23</sub> was detected among isolated *A. baumannii* strains in Riyadh and the Eastern Province with 53% and 75.5% of prevalence rates, respectively [30]. In Germany, Gamal Wareth et al., showed that the *bla*<sub>OXA-23</sub> gene was found in 14% of isolated *A. baumannii* strains of human origin [31], which is lower than prevalence reported in our study. Regarding other  $\beta$ -lactamases classes, our study showed that 6.9% of the isolates had *bla*<sub>TEM-2</sub> gene. Bacteria synthesize this gene are generally from the *Enterobacteriaceae* family, and this gene was described from *Escherichia coli* and *Klebsiella* clinical isolates in India, and subsequently reported in *A. baumannii* strains [26].

Interestingly 1 strain harbored the gene coding for metallo- $\beta$ -lactamase NDM-1. *Bla*<sub>NDM-1</sub> were carried along with *bla*<sub>OXA-51</sub>. The prevalence of *bla*<sub>NDM-1</sub> was 3.4% which is lower than recently reported in Africa namely Nigeria (38.1%) [32], Tunisia (3.6%) [19].

## Conclusion

Carbapenem resistance in Senegalese strains of *A. baumannii* is predominantly due to the worldwide disseminated gene *bla*<sub>OXA-23</sub>, with a subset of strains due to NDM-1. These AB-MDR strains were mainly isolated in ICUs with limited treatment options. Nevertheless, the use of colistin, a polypeptide antibiotic, as an alternative for infections caused by carbapenem-resistant Gram-negative bacilli should be considered in Senegal. Systemic molecular surveillance in the “One Health” network should be established for further efficient monitoring of MDR strains.

**Comment [M60]:** Replace with “However,”

**Comment [M61]:** Justify the whole paragraph

#### COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

#### References

1. Bouvet PJM, Grimont PAD. "Taxonomy of the genus *Acinetobacter* with the recognition of *Acinetobacter baumannii* sp. Nov., *Acinetobacter haemolyticus* sp. Nov., *Acinetobacter johnsonii* sp. Nov., and *Acinetobacter junii* sp. Nov. and emended descriptions of *Acinetobacter calcoaceticus* and *Acinetobacter lwoffii*." Int J Syst Bacteriol. 1986; 36:228-240.
2. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of *Acinetobacter* infections: A century of challenges. Clin Microbiol Rev 2017; 30(1):409-447.
3. Raro OHF, Gallo SW, Ferreira CAS, Oliveira SD. Carbapenem-resistant *Acinetobacter baumannii* contamination in an intensive care unit. Rev Soc Bras Med Trop. 2017; 50(2):167-172.
4. Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL, et al. *Acinetobacter baumannii* nosocomial infections during an outbreak in a burn unit. Int J Infect Dis. 2019; 79:179-184.
5. Tow KL, Weng TS. Pneumonia in the tropics. Respirology. 2018; 23(1):28-35.
6. Shi J, Sun T, Cui Y, Wang C, Wang F, Zhou Y, et al.. Multidrug resistant and extensively drug resistant *Acinetobacter baumannii* hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit. BMC Infect Dis. 2020; 20:597.
7. Griffith ME, Ceremuga JM, Ellis MW, Guymon CH, Duane R, Hospenthal DR, et al. *Acinetobacter* skin colonization of US Army soldiers. Infect Control Hosp Epidemiol. 2006; 27:659-661.

8. Bian X, Chen Y, Chen D, Jian Li J, Zhang J. Dose Optimization of Colistin Combinations against Carbapenem-Resistant *Acinetobacter baumannii* from Patients with Hospital-Acquired Pneumonia in China by Using an *In Vitro* Pharmacokinetic/Pharmacodynamic Model. *Antimicrob Agents Chemother*. 2019; 63(4):e01989-18.
9. Nordmann P, Poirel P. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. *Clin Infect Dis*. 2019; 69(Suppl 7):S521-S528.
10. Iwata S, Tada T, Hishinuma T, Tohya M, Oshiro S, Kuwahara-Arai K, et al. Emergence of Carbapenem-Resistant *Providencia rettgeri* and *Providencia stuartii* Producing IMP-Type Metallo-beta-Lactamase in Japan. *Antimicrob Agents Chemother*. 2020; 64(11):e00382-20.
11. Perez P, Innes GK, Walters MS, Mehr J, Arias J, Greeley R, et al. Increase in Hospital-Acquired Carbapenem-Resistant *Acinetobacter baumannii* Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020. *MMWR Morb Mortal Wkly Rep*. 2020; 69(48):1827-1831.
12. Victor UN, Chiedozie KO, Eziyi IK. Multidrug Resistant *Acinetobacter* Infection and Their Antimicrobial Susceptibility Pattern in a Nigerian Tertiary Hospital ICU. *Afr J Infect Dis*. 2014; 8(1):14-18.
13. Lowe M, Ehlers MM, Ismail F, Peirano G, Becker PJ, Pitout JDD, et al. *Acinetobacter baumannii*: Epidemiological and Beta-Lactamase Data From Two Tertiary Academic Hospitals in Tshwane, South Africa. *Front Microbiol*. 2018; 9:1280-89.
14. Cheikh HB, Domingues S, Silveira E, Kadri Y, Rosário N, Mastouri M, et al. Molecular characterization of carbapenemases of clinical *Acinetobacter baumannii*-*calcoaceticus* complex isolates from a University Hospital in Tunisia. *Biotech*. 2018; 8(7): 297-305.
15. Mananzhe RI, Zar HJ, Nicol MP, Kaba M. The spread of carbapenemase-producing bacteria in Africa: a systematic review *J Antimicrob Chemother* 2015; 70(1):23-40.
16. Société Française de Microbiologie. Détermination de la sensibilité aux antibiotiques: CASFM/ EUCAST : Société Française de Microbiologie Ed ; 2015; p.7-15.
17. Kempf M, Rolain JM, Diatta G, Azza S, Samb B, Mediannikov O, et al. Carbapenem resistance and *Acinetobacter baumannii* in Senegal: the paradigm of a common phenomenon in natural reservoirs *PLoS One* . 2012; 7(6):e39495.

18. Anane YA, Apalata T, Vasaikar S, Okuthe GE, Songca S. Molecular Detection of Carbapenemase-Encoding Genes in Multidrug-Resistant *Acinetobacter baumannii* Clinical Isolates in South Africa. *Int J Microbiol*. 2020;7380740.
19. Jaidane N, Naas T, Oueslati S, Bernabeu S, Boujaafar N, Bouallegue O, al. Whole genome sequencing of NDM-1-producing ST85 *Acinetobacter baumannii* isolates from Tunisia. *Int J Antimicrob Agents*. 2018; 52(6):916-921.
20. Mahamat A, Bertrand X, Moreau B, Hommel D, Couppie P, Simonnet C, al. Clinical epidemiology and resistance mechanisms of carbapenem-resistant *Acinetobacter baumannii*, French Guiana, 2008-2014. *Int J Antimicrob Agents*; 2016 ;48(1):51-55.
21. Yadav SK, Bhujel R, Hamal P, Mishra SK, Sharma S and Sherchand JB. Burden of Multidrug-Resistant *Acinetobacter baumannii* Infection in Hospitalized Patients in a Tertiary Care Hospital of Nepal. *Infect Drug Resist*. 2020; 13:725-732.
22. Motbainor H, Beredes F, Motbainor WM. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study. *BMC Infect Dis*, 2020; 20(1):92:4811-4818.
23. Jiang M, Liu L, Ma Y, Zhang Z, Li N, Zhang F, al. Molecular Epidemiology of Multi-Drug Resistant *Acinetobacter baumannii* isolated in Shandong, China. *Front Microbiol*, 2016;7:1687.
24. L  m TT, N  rnberg S, Claus H, Vogel U. Molecular epidemiology of imipenem resistance in invasive *Haemophilus influenzae* infections in Germany in 2016. *J Antimicrob Chemother*. 2020 Aug 1;75(8):2076-2086.
25. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. *Med Mal Infect* 2014; 44:51-56.
26. Joshi PR, Acharya M, Kakshapati T, Leungtongkam U, Thummeepak R, Sutthirat S. "Co-existence of blaOXA<sub>23</sub> and bla<sub>NDM-1</sub> genes of *Acinetobacter baumannii* isolated from Nepal: antimicrobial resistance and clinical significance". *Antimicrob Resist Infect control*, 2017; 6:21.
27. Luo TL, Alexander HR, Srinivasan U, Kaye KS, Foxman B. Association of blaOXA<sub>23</sub> and bap with the persistence of *Acinetobacter baumannii* within major helatcare system. *Front Microbiol* 2015; 6:182.
28. Rafei R, Pailhori  s H, Hamze M, Eveillard M, Mallat H, Dabboussi F, et al. Molecular epidemiology of *Acinetobacter baumannii* in different hospitals in Tripoli,

Lebanon using bla<sub>OXA-51-like</sub> sequence based typing. BMC Microbiol 2015; 15:103-110.

**Comment [M62]:** It should be in same page

29. Rodríguez CH, Yarhui NB, Nastro M, Quezada TN, Cañarte GC, Ventura RM, et al. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* in South America. J Med Microbiol 2016, 65:1088-1091.
30. Abdalhamid B, Hassan H, Itbaileh A, Shorman M. Characterization of carbapenem-resistant *Acinetobacter baumannii* clinical isolates in Saudi Arabia. New Microbiol 2014; 37:65-73.
31. Wareth G, Brandt C, Lisa D, Sprague LD, Neubauer H, Pletz MW. WGS based analysis of acquired antimicrobial resistance in human and no-human *Acinetobacter baumannii* isolates from German perspective. BMC Microbiol. 2021; 21(1):210-223.
32. Ogbolu DO, Alli OAT, Oluremi AS, Ogunjimi YT, Ojebode DI, Dada V, et al. Contribution of NDM and OXA-type carbapenemases to carbapenem resistance in clinical *Acinetobacter baumannii* from Nigeria. Infect Dis 2020; 52(9):644-650.